Research programme: delta opioid receptor antagonist - Southern Research Institute/Ernest Gallo Clinic and Research Center

Drug Profile

Research programme: delta opioid receptor antagonist - Southern Research Institute/Ernest Gallo Clinic and Research Center

Alternative Names: SoRI-9409

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Southern Research Institute
  • Developer Ernest Gallo Clinic and Research Center; Southern Research Institute
  • Class Morphine derivatives
  • Mechanism of Action Opioid delta receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Alcoholism

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Alcoholism in USA
  • 11 Sep 2008 Pharmacodynamics data from a preclinical trial in Alcoholism released by Southern Research Institute
  • 11 Sep 2008 Preclinical trials in Alcoholism in USA (Intraperitoneal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top